The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized, double-blind, phase 3 TRUST-IV study of adjuvant taletrectinib vs placebo in patients with stage IB–IIIA ROS1+ non-small cell lung cancer (NSCLC).
 
Alexander Spira
Leadership - Next Oncology (Inst)
Honoraria - Abbvie; Abbvie; Abbvie; Amgen; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Lilly; Merck; Novartis; Prelude Therapeutics; Takeda
Consulting or Advisory Role - Amgen; ArriVent Biopharma; AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Black Diamond Therapeutics; Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); crispr therapeutics; Daiichi Sankyo/Astra Zeneca; GlaxoSmithKline; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Lilly; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Regeneron; Revolution Medicines; Sanofi; Sanofi; Synthekine; Takeda
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Alkermes (Inst); Amgen (Inst); ArriVent Biopharma (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; lepu biopharma (Inst); Lilly (Inst); Loxo (Inst); Loxo (Inst); Macrogenics (Inst); Medikine (Inst); MedImmune (Inst); mersana (Inst); nalo therapeutics (Inst); Novartis (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); Regeneron (Inst); Revolution Medicines (Inst); Revolution Medicines (Inst); Roche (Inst); Rubius Therapeutics (Inst); Scorpion Therapeutics (Inst); Synthekine (Inst); Synthekine (Inst); Takeda (Inst); Tango Therapeutics (Inst)
 
Alexander Drilon
Stock and Other Ownership Interests - mBrace; Treeline Biosciences
Honoraria - Answers in CME; AstraZeneca; Bristol Myers Squibb Foundation; Clinical Care Options/NCCN; i3 Health; Ignyta/Genentech/Roche; Liberum; Loxo/Bayer/Lilly; OncLive/MJH Life Sciences; PER; Remedica; Research to Practice
Consulting or Advisory Role - Anheart Therapeutics; Axis Pharma; Bayer; Boundless Bio; Clinical Care Options; EcoR1 Capital; EMD Serono/Merck; Journal of the National Comprehensive Cancer Network; Liberum; Lilly; Med Learning; Medscape; Melendi; Monte Rosa Therapeutics; MORE Health; Novartis; Nuvalent, Inc.; Ology Medical Education; PeerView; Repare Therapeutics; touchIME; Treeline Biosciences; Zymeworks
Patents, Royalties, Other Intellectual Property - Osimertinib Selpercatinib; Wolters Kluwer (Royalties for Pocket Oncology)
Other Relationship - Anheart Therapeutics (Inst); Bayer (Inst); Boundless Bio (Inst); Bristol Myers Squibb Foundation (Inst); Exelixis (Inst); Lilly (Inst); Nuvalent, Inc. (Inst); Pfizer (Inst); Regeneron (Inst); Roche/Genentech (Inst); Triana (Inst)
 
Jonathan Goldman
Honoraria - Abbvie; AstraZeneca; Genentech; Lilly; Summit Therapeutics
Consulting or Advisory Role - AbbVie; AstraZeneca; Genentech; Lilly; Summit Biomedical
Research Funding - Abbvie (Inst); Advaxis (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Lilly (Inst); Lyell Immunopharma (Inst); Pfizer (Inst); Summit Biomedical (Inst); Systimmune (Inst)
Travel, Accommodations, Expenses - Summit Therapeutics
 
Narjust Florez
Employment - Dana Farber Cancer Hospital
Leadership - IASLC
Consulting or Advisory Role - AstraZeneca; Catalyst Pharmaceuticals; Daiichi Sankyo/Astra Zeneca; Genentech; Janssen; Jazz Pharmaceuticals; Johnson & Johnson/Janssen; Merck; Mirati Therapeutics; Novocure; Nuvalent, Inc.; Nuvation Bio; Pfizer; Regeneron
Research Funding - AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo/Astra Zeneca; Genentech
Other Relationship - Clinical Care Options; CME Outfitters; IDEOlogy Health; Medscape; OncLive/MJH Life Sciences; PER; Precisca
 
Petros Christopoulos
Honoraria - Accord Healthcare; AstraZeneca; BeOne; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Johnson & Johnson/Janssen; Johnson & Johnson/Janssen (Inst); Merck Serono; Novartis; Pfizer; PharmaMar (Inst); Pierre Fabre; Roche; Takeda
Research Funding - Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Merck Serono (Inst); Roche (Inst); Takeda (Inst)
 
Maurice Perol
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Gilead Sciences; GlaxoSmithKline; IPSEN; Janssen Oncology; Lilly; Merck Sharp & Dohme; Novartis; Novocure; Nuvation Bio; Pfizer; Roche/Genentech; Sanofi; Takeda
Research Funding - Takeda (Inst)
Expert Testimony - Amgen; AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Merck Sharp & Dohme; Pfizer; Roche; Takeda
 
Dih-Yih Chen
Employment - Nuvation Bio Inc.
Stock and Other Ownership Interests - BeOne Medicines
 
Feiwu Ran
Employment - Nuvation Bio
Travel, Accommodations, Expenses - Nuvation Bio
 
Xianyu Zhang
Employment - Nuvation Bio Inc.
Stock and Other Ownership Interests - Nuvation Bio Inc.
 
Geoffrey Liu
Honoraria - Abbvie; Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; emd serono; Jazz Pharmaceuticals; Merck; novartis; nuvation bio; pfizer; Roche Canada; Takeda
Consulting or Advisory Role - AstraZeneca/MedImmune; novartis; pfizer; Roche Canada; takeda
Speakers' Bureau - AstraZeneca; Pfizer; Takeda
Research Funding - AstraZeneca/MedImmune (Inst); Boehringer Ingelheim; roche (Inst); Takeda
 
Caicun Zhou
Leadership - IASLC BOD
Honoraria - Akeso Biopharma; Alice; Amoy Diagnostics; Anheart Therapeutics; Hengrui Therapeutics; Innovent Biologics; Lilly; Luye Pharma; Merck Sharpe and Dohme; MSD; QiLu Pharmaceutical; Sanofi; TopAlliance BioSciences Inc
Consulting or Advisory Role - Amoy Diagnostics; Hengrui Therapeutics; Innovent Biologics; QiLu Pharmaceutical; Top Alliance BioScience